long intergenic non-protein coding RNA 1922Genealiases: []
Q-omics provides the consensus-scored LINC01922 profile across patient tissues and cancer cell-line models. LINC01922 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01922 is differentially expressed in 3, with the highest sampling consensus in ESCA. Additionally, LINC01922 RNA expression shows 6,388 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, ESCA, and STAD as cancer lineages where LINC01922 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01922 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01922 survival associations across molecular data types. LINC01922 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01922 RNA expression–survival associations across cancer types. High LINC01922 expression shows unfavorable associations in KIRC, LIHC, BRCA, THCA and PAAD, but favorable associations in CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01922 RNA expression.
This table summarizes LINC01922 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01922. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01922 shows lower tumor expression in THCA and higher tumor expression in ESCA and KIRC. The ESCA box plot shows higher LINC01922 RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p = .037).
This table shows molecular features associated with LINC01922 in patient tissues and cancer cell lines. In patient samples, LINC01922 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
